On Monday, Pliant Therapeutics Inc (NASDAQ: PLRX) opened lower -11.73% from the last session, before settling in for the closing price of $1.62. Price fluctuations for PLRX have ranged from $1.26 to $16.52 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -52.88%. Company’s average yearly earnings per share was noted 23.30% at the time writing. With a float of $52.99 million, this company’s outstanding shares have now reached $60.86 million.
Let’s determine the extent of company efficiency that accounts for 171 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Pliant Therapeutics Inc (PLRX) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Pliant Therapeutics Inc is 13.46%, while institutional ownership is 96.73%. The most recent insider transaction that took place on Jan 17 ’25, was worth 587,150. In this transaction President and CEO of this company sold 52,419 shares at a rate of $11.20, taking the stock ownership to the 430,517 shares. Before that another transaction happened on Jan 17 ’25, when Company’s Chief Financial Officer sold 20,148 for $11.20, making the entire transaction worth $225,680. This insider now owns 262,608 shares in total.
Pliant Therapeutics Inc (PLRX) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.63 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 23.30% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 15.87% during the next five years compared to -78.30% drop over the previous five years of trading.
Pliant Therapeutics Inc (NASDAQ: PLRX) Trading Performance Indicators
Check out the current performance indicators for Pliant Therapeutics Inc (PLRX). In the past quarter, the stock posted a quick ratio of 10.91.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.47, a number that is poised to hit -0.77 in the next quarter and is forecasted to reach -2.44 in one year’s time.
Technical Analysis of Pliant Therapeutics Inc (PLRX)
Looking closely at Pliant Therapeutics Inc (NASDAQ: PLRX), its last 5-days average volume was 4.29 million, which is a jump from its year-to-date volume of 2.89 million. As of the previous 9 days, the stock’s Stochastic %D was 12.88%. Additionally, its Average True Range was 0.62.
During the past 100 days, Pliant Therapeutics Inc’s (PLRX) raw stochastic average was set at 1.15%, which indicates a significant decrease from 7.73% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 386.48% in the past 14 days, which was higher than the 227.95% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $8.1603, while its 200-day Moving Average is $11.6772. However, in the short run, Pliant Therapeutics Inc’s stock first resistance to watch stands at $1.6065. Second resistance stands at $1.7831. The third major resistance level sits at $1.8963. If the price goes on to break the first support level at $1.3167, it is likely to go to the next support level at $1.2035. Should the price break the second support level, the third support level stands at $1.0269.
Pliant Therapeutics Inc (NASDAQ: PLRX) Key Stats
There are currently 61,236K shares outstanding in the company with a market cap of 87.57 million. Presently, the company’s annual sales total 1,580 K according to its annual income of -161,340 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -57,760 K.
